An initiative of cardiologists and the Dutch CardioVascular Alliance has resulted in the start of the CAPACITY COVID registry, to collect CV data of COVID-19 patients. The initiators call to join now!
Prof. Asselbergs calls to participate in the CAPACITY COVID-19 registry, a CV supplement to the existing ISARIC and WHO registry, to collect information on CV variables during the COVID-19 pandemic.
The ACC’s Interventional Council and SCAI have listed some of the specific implications of COVID-19 on practice in the catheterization laboratory.
A review article describes the prevalence rates of CVD in patients with COVID-19 with a focus on myocardial injuries in COVID-19 patients and heart transplantations in times of the current pandemic.
A review article published in JACC outlines CV considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic.
This viewpoint article draws attention towards acute and possible long-term implications of coronavirus infections, such as COVID-19, on the cardiovascular system.
Following the ESC statement, a joint statement of the HFSA, ACC and AHA has now been published on continued use of RAASi during the COVID-19 pandemic.
The ESC Council on Hypertension has released a statement, strongly recommending to continue treatment of ACEi and ARBs in times of the COVID-19 pandemic, as evidence for harmful effects of these drugs in context of COVID-19 is lacking.
The ACC has released a clinical bulletin providing literature on acute cardiac complications of COVID-19, implications for CV patients and clinical guidance and recommendations for cardiac-specific preparedness.